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Abstract 
Biomarker-guided trials have drawn considerable attention as they promise to lead 
to improvements in the benefit-risk ratio of treatments and enhanced opportunities 
for drug development. A variety of such designs have been proposed in the 
literature, many of which have been adopted in practice.  
Implementing such trial designs in practice can be challenging,  and identifying 
those challenges was the main objective of a workshop organised by the MRC Hubs 
for Trials Methodology Research Network’s Stratified Medicine Working Group in 
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March 2017. Participants reflected on completed and ongoing biomarker-guided 
trials to identify the practical challenges encountered. Here, the key challenges 
identified during the workshop including those related to funding, ethical and 
regulatory issues, recruitment, monitoring of samples and laboratories, biomarker 
assessment, and data sharing and resources, are discussed.  
Despite the complexities often associated with biomarker-guided trials, the 
workshop concluded that they can play an important role in advancing the field of 
personalized medicine. Therefore, it is important that the practical challenges 
surrounding their implementation are acknowledged and addressed. 
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Introduction 
Clinical trials are essential for testing the safety and efficacy of new 
treatments. Increasingly, biomarkers are becoming an integral part of clinical trials 
as they are considered key tools in the identification of patient sub-populations 
most likely to benefit or conversely to incur adverse reactions from a given 
treatment{Landeck, 2016 #1;Bailey, 2014 #2;La Thangue, 2011 #20;Vargas, 2016 #21}. 
Hence, so-called biomarker-guided trial designs are pivotal in advancing the field of 
personalized medicine which aims to give ‘the right treatment to the right patient, 
at the right dose at the right time’ (1). Consequently several biomarker-guided trial 
designs which test the effectiveness of a biomarker-guided approach to treatment 
have been proposed in the literature, some of which have been adopted in practice. 
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Detailed reviews of biomarker-guided designs have been published (3-6) and are 
also available via an online tool “BiGTeD” (http://www.bigted.org/). 
A one-day workshop organised by the MRC Hubs for Trials Methodology 
Research Network’s Stratified Medicine Working Group (SMWG) was held in 
London in March 2017. The aim was to identify and explore the key practical 
challenges arising when conducting a biomarker-guided clinical trial. The 
workshop brought together 25 participants with practical experience in conducting 
biomarker-guided trials from various disciplines including statisticians, trial 
managers, information systems specialists and clinicians. This workshop was 
motivated by feedback from trialists and previous literature (3, 4) suggesting that 
there are substantial challenges associated with undertaking trials adopting these 
types of designs. 
Specific trials were utilised as exemplars to aid discussion and these are the 
focus of the first part of this paper. The second part provides an overview of the 
practical challenges raised at the workshop and identified from delegates’ 
experiences, together with some of our own reflections on those issues from our 
methodology reviews and simulation studies (3, 4, 7). Issues considered include 
funding, ethical and regulatory issues, recruitment, monitoring of samples and 
laboratories, biomarker assessment, data sharing, and resourcing. A summary table 
is also provided of each trial’s key characteristics with examples of some of the 
challenges they faced (Table 1). 
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Biomarker-guided trials used as exemplars 
The majority of trials discussed at the workshop are oncology trials simply because 
oncology dominates the field of personalised medicine. Many of the challenges 
identified apply equally to trials in other clinical areas.  
i) The National Lung Matrix Trial (NLMT; ongoing trial) (8): This is a phase II 
non-randomized umbrella trial consisting of multiple single arm trials within one 
protocol. The aim of the trial is to investigate a range of new treatments 
hypothesized to be of benefit to specific molecularly-defined cohorts of patients 
with advanced non-small cell lung cancer (NSCLC) and for whom surgery and 
radiotherapy are not deemed appropriate treatments.  
NLMT runs alongside the Cancer Research UK Stratified Medicine 
Programme (SMP2), where a next generation sequencing 28 gene panel test is used 
to assess the genetic profile of trial participants which then determines which single 
arm trial (strata), and hence drug, they are assigned to. The trial adopts a Bayesian 
adaptive design with an interim analysis at 15 patients for each strata and final 
analysis of a target group of 30 patients per strata. The trial was designed to 
evaluate a common set of outcome measures with primary outcome measures 
chosen specifically for each treatment arm. A clinically relevant signal of efficacy is 
defined: for cytostatic agents as median progression-free survival greater than 3 
months; for other agents as rates of objective response{Eisenhauer, 2009 #19} or 
durable clinical benefit (defined as remaining free of disease progression at a CT or 
MRI scan approximately 24 weeks after starting treatment, or thereafter) with a 
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critical cut-off greater than 30% for single agent and 40% for combination therapy 
arms. 
ii) Phase II trial of olaparib in patients with advanced castration resistant 
prostate cancer (TOPARP) (ongoing at time of workshop, now closed to 
recruitment) (9): This is an open label, phase II, single arm, 2 part adaptive design 
trial for biomarker-driven selection based on response rate. It aims to evaluate the 
anti-tumour activity of the Poly (ADP-ribose) polymerase (PARP) inhibitor, 
olaparib, in metastatic castration resistant prostate cancer (mCRPC) and to identify 
molecular signatures for PARP inhibitor sensitivity with a pre-planned analysis to 
identify a biomarker-defined sensitive subgroup. In the first part unselected (i.e. 
without biomarker-guided patient selection) mCRPC patients are all treated with 
olaparib. If during the first part the response rate is high (i.e., ≥ 50% responding) 
the trial will close and a randomized placebo controlled clinical trial to evaluate the 
efficacy and safety of olaparib in these unselected mCRPC patients is undertaken. If 
the response rate is low (i.e. response rate < 10%), the trial is stopped. If in the 
intermediate range (10-50% responding), potential biomarkers of response are 
investigated and if a potential biomarker is identified, with those positive for the 
biomarker having a high response rate (≥50%), the trial continues to the second part 
where only biomarker selected patients are included. 
iii) Adaptive multi-arm phase II trial of maintenance targeted therapy after 
chemotherapy in metastatic urothelial cancer (ATLANTIS) (ongoing) (10): This is an 
adaptive multi-arm randomized phase II trial which aims to explore whether 
maintenance targeted therapy after chemotherapy, with treatment randomisation 
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based on biomarker profile, delays time to progression and increases overall 
survival for patients with advanced urothelial cancer.  The initially planned 
biomarker is androgen receptor status with patients who are androgen receptor 
positive randomised between enzalutamide and placebo.  The “adaptive” element 
of ATLANTIS is the ability to add comparisons in other biomarker selected 
subgroups (for example a comparison of rucaparib v placebo is planned in patients 
who have BRCA1 or BRCA2 mutations, either as a somatic or germline event, or 
with evidence of homologous recombination deficiency) 
 
iv) PRIMUS001 (ongoing) (11): This is an adaptive phase II trial, with biomarker 
evaluation integrated into the trial which aims to assess the efficacy of FOLFOX-A 
(FOLFOX and nab-paclitaxel) when compared to AG (nab-paclitaxel and 
gemcitabine) in patients with metastatic pancreatic cancer, both in a biomarker-
positive group and in biomarker-unselected patients.  PRIMUS001 will determine 
whether there is a benefit from FOLFOX-A compared to AG, and if there is a benefit 
whether this is in all patients or in biomarker +ive patients only. As the study 
proceeds there are a number of interim analyses following which subsequent 
recruitment may be restricted to biomarker +ve patients if there is no evidence of 
benefit of FOLFOX-A compared to AG in biomarker unselected patients. 
 
v) SALONICA (planned trial): This is a stratified adaptive trial in ovarian 
cancer aiming not only to detect the key genomic determinants of response and 
resistance to neoadjuvant platinum-base chemotherapy in high-grade serous 
ovarian cancer but also to identify and validate putative biomarkers as well as test 
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several novel drugs and corresponding putative biomarkers in women with poor 
response to neoadjuvant platinum chemotherapy through a phase II trial platform.  
SALONICA is initially based on a sequence of single-arm biomarker unselected 
phase II designs, but as information on the mutational changes and associated 
biomarkers in ovarian cancer accumulates the ambition is to move to a design based 
on Bayesian Adaptive Randomisation (BAR). 
vi) TASTER (planned trial): This trial aims to identify predictors of response to 
novel combination therapies in Chronic Myeloid Leukaemia (CML) patients who do 
not respond to tyrosine kinase inhibitor therapy. Both in vivo models of drug 
response and clinical data will be used to identify molecular signatures of stem cell 
resistance and build and validate predictive models of drug response from which 
the best treatment for a patient can be selected.   The success of the predictive model 
will be assessed in standard single arm phase II design for each candidate novel 
combination.  
 
vii) POETIC (Peri-Operative Endocrine Therapy for Individualizing Care) 
(ongoing trial) (12, 13): This is a randomized, multicentre phase III trial which aims 
to investigate whether having perioperative aromatase inhibitor (AI) therapy for 
postmenopausal women with ER+/PgR+ positive invasive breast cancer is more 
effective than having standard care alone. 4,476 patients were recruited from 130 
UK centres. Patients received either AI therapy for 4 weeks (two weeks before and 
two weeks after surgery) or no peri-operative AI therapy. Whilst ER is a well 
established biomarker it is not usually used to direct therapy so early in the patient 
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pathway, thus new procedures had to be established for the trial to ensure its 
measurement was available at the time of diagnosis based on a core biopsy. 
viii) FOCUS4 trial (ongoing trial) (14): This is an umbrella clinical trial 
consisting of parallel, molecularly stratified randomized comparisons in patients 
with metastatic colorectal cancer (mCRC). Patients with newly diagnosed mCRC 
are registered into the trial and commence their standard first line chemotherapy 
which typically lasts for approximately 16 weeks. During this time, a sample of 
their tumour is sent away to one of two dedicated FOCUS4 laboratories who 
perform genomic and molecular tests on the tumour. This enables stratification of 
the patients into one of a number of pre-specified molecular subgroups (called 
cohorts). Patients are then offered entry into a randomized trial (called comparison) 
testing a specific targeted therapy for their subtype of cancer. All these comparisons 
are randomized and controlled and wherever possible use a placebo in the control 
group. 
ix) EU-PACT trial (completed trial) (15): This was a pragmatic, single-blind, 
randomised controlled trial to determine whether genotype-guided dosing of the 
anticoagulant warfarin is superior to standard dosing. Patients commencing 
warfarin were randomised to one of two trial arms. Those randomised to the 
genotype-guided dosing arm had their genotype tested at three genetic variants 
using a point of care test, with results available within two hours. Their genotype 
was fed into a computer based loading dose algorithm, together with demographic 
and clinical information, and a personalised loading dose recommended for the first 
three days. Similar information was then fed into a maintenance dose algorithm to 
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determine dose on days 4 and 5 of treatment. From day 6 dosing was according to 
standard clinical care. Those randomised to the control arm had their loading and 
subsequent doses calculated according to standard approaches, with no reference to 
genotype. All patients were followed up for three months and their anticoagulation 
control assessed. 
Challenges 
Funding issues 
Biomarker-guided trials often have a complex design – both scientifically and 
logistically and it is therefore not surprising that the resources required are typically 
considerably higher than for trials with more simple designs. Nonetheless, funders 
show substantial enthusiasm for supporting biomarker-guided trials, since it is 
recognized that despite increased costs the trial may well be more efficient in 
demonstrating patient benefit. When considering the additional resources required, 
the increased administrative burden is a major factor: for instance, in umbrella type 
designs necessary documentation and multiple approvals need to be repeated for 
each treatment group of the trial. How those amendments are handled (e.g. the 
addition of a new trial group), can depend on  cost. For example, it is typical for 
changes that don’t require additional funding from charitable or public bodies 
(generally where funding is provided by a pharmaceutical partner) to be 
implemented quickly without additional approvals, but if the amendment is likely 
to require additional funding support then it is necessary for it to go through the 
more classic route of peer-review and research grant approval. 
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Further, despite the attractive flexibility they bring, by virtue of their design 
the overall costs of adaptive trials in particular are difficult to predict at the outset 
due to the uncertainty surrounding their future direction, for example the number 
of additional/discontinued groups and final sample size. In addition, with science 
evolving at such a fast pace, biomarker assessment costs may change with changing 
technologies. Open communication between those involved in planning such a trial 
and funders is important from the outset to determine the best way to handle 
applying for  funding.  Such open communication will also help inform funders on 
the implications of using such designs for their funding streams. 
So that overall costs can be considered, and to avoid triggering further full 
processes for committee approval with the addition of each new trial group, it can 
be advantageous for  applicants to provide details on potential additions at the 
outset to allow funders to forecast and earmark the foreseeable additional budget 
and provide approval in principle. A similar agreement is already in place with 
CRUK for NLMT. So, a researcher putting an application for an umbrella trial, for 
example to include initial trial groups A to D, would be required to also estimate 
how much it would cost to add groups E, F, and G at time points X,Y and Z. 
Understandably, providing such predictions of future costs  can be difficult as it 
requires knowledge not only of the approximate size of the trial groups to be added 
(or indeed removed) within those changes, but also the time point at which they 
will be added and the approximate end date.  
Further, including additional forecasted costs could easily make a trial 
unattractive to funders, with projected total costs for a large trial using up the entire 
11 
 
budget for a funding call. Funders will always be faced with many competing 
funding requests, many of which will have simpler and easier to understand 
designs and more transparent budgets.  
It is anticipated however that once many of the currently ongoing trials are 
completed, there will be a better understanding of the value for money offered by 
such trial designs. However it is important to note that this could be misleading in 
itself since it is widely recognised in the trial community that many such trials may 
have been significantly under-resourced. Quite often, it is the Clinical Trial Units 
(CTU) costs (e.g. trial management, trial monitoring, statistical analysis and 
oversight) that are compromised.  
One possible model is to fund the molecular screening platform as a separate 
venture from the trial itself and run them as two interrelated studies. This can be 
seen in NLMT where the Stratified Medicine Programme 2 (SMP2) provides a 
comprehensive screening programme funded by Cancer Research UK in 
collaboration with pharmaceutical partners and the NLMT is funded as a separate 
Cancer Research UK trial grant. SMP2 provides the patients for NLMT so the 
success of the trial is entirely predicated on the success of SMP2 and clearly close 
interaction between the two separate projects is essential. Such a funding model can 
be appropriate if the stratifying biomarkers involved are novel and outside of 
routine testing and provides transparency in terms of the costs for the two key 
major elements in such a trial.  
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FOCUS4 provides an example of how exploring alternative funding 
arrangements led them to successfully securing funding for their trial. Joint funding 
was applied for between CRUK and the Efficacy and Mechanism Evaluation 
(MRC/NIHR EME) Programme. Every time a new cohort is added an EME Sub 
Board meeting is held with representatives from CRUK and EME. A scientific 
rationale and funding model has to be presented by the investigators to this Sub 
Board for scrutiny. This approach has worked well and could be a viable option for 
similar trials as long as the funding bodies are encouraged by the efficiencies and 
opportunities of joint long-term commitments. 
There has also been some confusion amongst researchers in the UK about who 
should fund the additional biomarker tests within a trial. It has previously been 
suggested that this is a National Health Service (NHS) cost since it is used to direct 
treatment, however since the test is often unavailable on the NHS, it could be 
considered to be a research cost. Another viewpoint is that, in the case of a test not 
yet implemented in practice, if the cost of the test in a research setting exceeds the 
hypothetical cost of using the test in routine practice, the additional cost should be 
covered by research funding, with the hypothetical costs associated with using the 
test in practice, being classed as (potentially excess) treatment costs. This situation 
may be slowly changing, however, as we move into an era where more biomarker 
tests are routinely undertaken in practice.  
Finally, an additional funding issue relates to whether the trial uses 
previously untested biomarkers or more established and validated ones; the former 
may incur additional costs for the development, validation and standardization of 
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appropriate assays, and delays in the expected start date. Further, issues with 
sample quality can cause problems for recruitment in situations where results are 
required with a tight turnaround, as can problems with the assay e.g. its sensitivity. 
In summary, detailed and early planning with clear communication between 
researchers and funders is vitally important to ensure that future trials can be fairly 
considered and appropriately funded. There is also room for learning, with those 
with practical experience of such trials sharing their knowledge and experiences 
with funding bodies as well as funding bodies, with their broader oversight across a 
spectrum of trials that they fund, sharing the same with researchers. These trials can 
appear overwhelming if viewed within the classical approvals paradigm but are not 
as complicated as is often believed. With some designs, they can be considered as a 
collection of individual separate trials with some additional biomarker analyses. If 
their benefits and limitations are communicated effectively, then they should be 
embraced rather than feared. 
Ethical and Regulatory Issues 
A key issue here is the different ways in which regulatory bodies choose to 
classify a biomarker-guided trial. For instance, there is an expectation that when 
adding a new Investigational Medicinal Product (IMP) to an umbrella trial there 
should also be a new CTA (Clinical Trial Authorization), which may not necessarily 
be required. Consideration needs to be given to the subtleties of adding a new IMP, 
for example if it comes from a different class of drugs than existing IMPs and with a 
different safety profile and changes the scientific intent of the trial a new CTA may 
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be entirely appropriate, whilst unnecessary with more similar IMPs.   It may also be 
believed that from a commercial perspective the trial will be testing, developing and 
marketing a companion diagnostic alongside the therapeutic, which is not always 
the case. Early discussion with the competent authority is strongly advised.  
Although the general consensus is that research ethics committees view these 
types of trials very positively, many ongoing administrative issues need to be 
addressed. Whilst an ethics committee might give overall ethics approval at the 
outset, it is often not clear how the addition of new trial groups will be approved 
later. Depending on local practice, amendments may not be reviewed, discussed 
and approved by a sub-committee; or may even come through simply as a 
chairman’s action. Consequently, the trial documents are perhaps not checked in 
the same way as the original application and the amendments may not receive the 
same level of scrutiny. In addition, there is inconsistency in what documentation 
ethics committees request for amendment approval, with some requesting a new 
submission and others seeking a major amendment. It is important that a 
collaborative relationship is maintained with the Health Research Authority (HRA) 
to ensure that administrative systems, paperwork, and version control are adapted 
to adequately deal with these types of amendments. Researchers with experience of 
running such trials are well placed to advise in this regard. 
Similar collaborative relationships also need to be maintained with the 
relevant regulatory authority (e.g. the Medicines and Healthcare products 
Regulatory Agency (MHRA) or EMA or FDA). For example, the name of a trial’s 
CTA is based on the initial treatment drugs included in the trial; however, these 
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may not be part of the trial for the whole duration of the trial (e.g. due to ineffective 
treatment groups being dropped and other promising ones being added) which can 
lead to confusion in terms of terminology. 
From the perspective of patients, some issues need to be considered relating 
to the informed consent process. There are examples of having to consent patients 
into the trial on the same day of diagnosis, for example so that a sample can be sent 
immediately for biomarker testing to avoid delaying treatment down the line, 
which clearly requires both careful and appropriate communication. Another issue 
could arise, particularly in oncology trials, due to the possibility that biomarker 
screening might fail requiring a second biopsy. Obtaining a second biopsy can be 
painful, have associated risks and be difficult be obtain if patients are not well 
enough. In such cases, it may or may not be appropriate to include a trial option for 
non-stratified patients (including those with failed biopsies), particularly if 
biomarker screening is invasive or has a high failure rate.  
Effective communication with patients is also fundamental to ensure a clear 
understanding of the purpose of biomarker trials, and whilst they are often about 
targeting treatments to patients most likely to benefit, they can also be about trying 
to avoid treatments in patients who are unlikely to benefit from them. This may aid 
acceptance by those not being offered an experimental treatment based on their 
biomarker profile. Whilst on the surface personalizing treatment may sound like the 
optimal solution, it should not be communicated as if a treatment will definitely 
work in a patient with given biomarker status, but rather is an approach that will 
mean it is potentially more likely to work. It is also essential that patients 
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understand that being screened for a biomarker does not guarantee they will be 
eligible for the trial, since they will often have to meet additional eligibility criteria. 
Further, there may be a delay in meeting eligibility criteria such that the trial is 
closed before the patient can be recruited.   
An additional ethical challenge can arise in trials, where genetic markers are 
being assessed, and susceptibility to certain other diseases are uncovered – so-called 
‘incidental’ findings, and this is a subject of much debate(16, 17). From the patient’s 
perspective, in theory this issue can be covered in the informed consent process by 
allowing them to opt-in or opt-out of information on incidental findings. In reality 
however, the issue is far more complex since making a truly informed decision 
would require the patient to have an extensive amount of specialist genetic 
counselling for numerous conditions unrelated to the primary reason for the genetic 
test. Further, it can pose a moral dilemma to those involved in conducting the trial. 
Whilst there are clear advantages arising from incidental findings which can be 
actioned medically, there is a risk of false positive findings, and knowledge of 
future disease risk and the anxiety it brings can do more harm than good in 
asymptomatic patients(17). Additionally, from the patients’ perspective, they can 
often mistakenly assume that having certain mutations in their tumour means an 
increased risk of disease in relatives. Hence, more careful communication is needed 
in order to clarify the difference between mutations in a tumour and germline 
mutations, and which type they are being tested for. 
In summary, several ethical and regulatory challenges can arise ranging from 
a lack of consistency surrounding administrative procedures to issues relating to 
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communications with patients. It is essential that accurate information about 
biomarker-guided trials is communicated to all relevant stakeholders so that they 
are aware of the characteristics and advantages of such trials. 
Recruitment 
Uncertainty in recruitment rates, especially in trials that include rare 
biomarker groups, can be a major dilemma. The prediction of recruitment rate into 
umbrella trials can be difficult due to several factors. One of these factors is 
uncertainty surrounding the estimated prevalence of each biomarker since this 
might not be accurately known at the design stage. The uncertainty is greater in the 
case of trials that evaluate multiple biomarkers as overlapping groups can occur (i.e. 
a single patient positive for multiple biomarkers). Another contributing factor is 
that the failure rate of laboratory diagnostic biopsies in the technology hubs is 
difficult to predict. The funders and sponsors regularly question whether the 
achieved recruitment rate is close to that projected. Recalculations and protocol 
amendments may be required, which can often be more complex for biomarker-
guided trials than for a traditional trial. Hence, a more flexible methodology is 
needed for predicting recruitment rate for these trials. Indeed, a more sophisticated 
statistical approach to prediction that incorporates the uncertainties could be 
considered in order to provide a realistic range for expected recruitment into each 
biomarker group. 
Recruitment issues can be patient related or researcher related. From the 
patients’ perspective, if there is considerable time between a patient undergoing 
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molecular screening and being approached about a treatment trial they may be 
fatigued or experiencing toxicity symptoms after first line treatment, or their disease 
may have progressed, or they may simply not be interested in the new drug and 
would like to take a break from treatment. In addition, having complex tissue 
sampling (mandatory fresh biopsies) is always a challenge for recruitment since 
some patients would prefer to not have such invasive testing, and in addition due to 
the complexity sampling may take some time in which case a patient’s status and 
ability to participate may have changed.  
From the researchers’ perspective, slow trial set up due to the necessary sample 
collection and processing procedures that need to be established not only delays 
recruitment but might also lead to study sites losing their enthusiasm. In turn, this 
may affect the motivation of commercial partners to get involved. Further problems 
can arise when it is difficult to predict recruitment timelines, as seen in the TOPARP 
trial.  It was difficult to accurately predict recruitment as there was a “lead site” 
effect at the Chief Investigator’s site.  Due to a change in the formulation of the 
novel agent it was necessary to initially only recruit patients at the lead site for 
safety reasons.  Complex sampling collection and processing requirements took 
external sites longer to establish and as a consequence the management of 
collaborators’ expectations (funders, sites, investigator and commercial partners) 
was challenging.  Additionally a higher screening failure rate was noted at external 
sites, potentially due to the population of patients seen. Therefore, screening 
activity at site was increased along with activity at the central lab/CTU. Due to the 
time to deliver biomarker results to sites, sites tested patients for the biomarker 
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earlier in the patient pathway than anticipated leading to a pool of biomarker 
patients waiting to be eligible for the trial and increased activity at the central 
laboratory and CTU. 
In addition, the dropout rate from trials can be significant, particularly where 
trials involve patients with rapidly progressing disease. For example, in the NLMT 
trial where patients with advanced lung cancer were considered, genetic profiling 
was undertaken on diagnostic samples whilst the patients were undergoing 
standard first line treatment and by the time they were ready to enter the trial after 
progression from first line treatment, the condition of many had deteriorated too 
much for them to participate. It is not uncommon for a patient to have died before 
the results are available. Even if they are still alive, the patient’s condition may have 
deteriorated or they may have decided they no longer want to be involved in the 
trial. Risk of dropout is further increased since once someone has been recruited, the 
schedule of trial assessments can be too demanding, and the patient may decide to 
take the simpler option of not partaking in the trial. Further, receiving a novel 
therapy may require travel to a more distant location and those with advanced 
disease may find it challenging to do so. The likelihood of dropping out can be 
reduced by ensuring rapid turnaround times for biomarker test results, which allow 
treatment to begin more quickly. 
To summarize, given the multiple factors impacting how likely patients will 
be identified, recruited and retained in a biomarker-guided trial, estimating an 
accurate rate of recruitment will always be difficult. It is suggested, therefore, that 
well-designed pilot and feasibility studies are undertaken prior to trial 
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commencement to ensure a more accurate understanding of recruitment rate as well 
as a smoother and more rapid process of site set-up. It is often more attractive to 
incorporate a feasibility study into the main trial, with in-built go/no go criteria, so 
that starting the trial itself is not unduly delayed. Laboratories should also be 
sufficiently equipped and efficient to deal with rapid biomarker analysis 
turnaround. It is important to note that the trials discussed here, and their 
associated recruitment challenges are some of the first of their kind, and that 
experience of working on these and other similar trials will also guide us in 
predicting more accurate and achieving better recruitment rates in future, as well as 
ease the process of site set-up.  
Monitoring samples and laboratories   
It is expected that good internal audit trails are in place within laboratories 
undertaking biomarker assessment for clinical trials, however logistical problems 
can occur in the transfer of results from laboratory to CTU. Often, results for 
exploratory biomarkers are batched with hundreds, or thousands of biomarker 
results transferred at a time, so it is important to agree on procedures for 
transferring the data accurately before trial commencement. Problems can arise 
when not all laboratory staff are trained in trials related GCP (Good Clinical 
Practice) and this is important to ensure that there is a sufficient audit trial and no 
breaches in confidentiality of biomarker data. Therefore, it is important that 
laboratories have a good understanding of GCP requirements. 
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Tracking patient samples requires a significant amount of work and 
coordination, and is often more complex than what is typically required from 
laboratory information management systems. For example, a first sample may be 
received and there might be insufficient tumour, meaning that another sample has 
to be requested. A full audit trail is required to ensure that the correct biomarker 
test result is used in the analysis. A significant amount of data cleaning is also 
typically required. 
In terms of the handling and tracking of samples, local research nurses, 
pathologists, laboratory staff as well as the CTU will be involved. In FOCUS4, a 
challenge arose with sample management in that patients could be registered up to 
12 weeks after starting their first line chemotherapy meaning that a fast turnaround 
was required at the laboratories to ensure biomarker results were received before 
the patients had ended their 16 weeks of first line therapy. Further difficulties arise 
when the tissue obtained was inadequate or is not viable and further requests for 
samples need to be made back to the original hospital pathology departments.  
To ensure optimal efficiency, it is recommended that lots of samples are 
batched up to be sent all at once instead of using additional resources on several 
small runs. However, this can lead to problems when lower than anticipated 
recruitment leads to further delays as labs wait for enough samples to justify 
running a batch. It is also not practical in smaller trials where a quick turnaround or 
‘fresh’ samples are essential.  
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Examples of additional problems with sample management were observed in 
FOCUS4, including resolution of pathology number discrepancies and failure to 
send GCP compliant documents to the CTU. Further, in NLMT, a particular 
challenge arose with the lab reports. Here, the genetic result reports did not state 
which strata in the trial the patient was eligible for, and thus the CTU personnel 
were required to read the complex reports and determine the appropriate treatment 
allocation for the patient. Not only was this an additional burden on CTU staff but 
required rigorous procedures to minimise the risk of error, including sign off of all 
allocations by the Chief Investigator. 
Another challenge associated with biomarker analysis is that science is 
advancing rapidly with many new opportunities arising in biomarker assessment. It 
is recommended that a separate lab manual is used outside the protocol in order to 
minimize any associated protocol amendments. 
In terms of ensuring completeness and quality of tissue samples received, 
communication and collaboration between clinicians and laboratory staff should be 
strengthened to ensure that samples are taken, stored and sent off in accordance 
with the protocol. In addition, the CTU’s central trial monitoring capabilities should 
be utilized to ensure efficient sample tracking. Strong collaboration between the 
CTU and the laboratory staff is essential given how dependent the success of a 
biomarker-guided trial is on accurate and timely delivery of lab results.  
23 
 
Biomarker assessment 
One major challenge during biomarker assessment can arise when samples 
are heterogeneous. This misclassification problem is less of an issue when patients 
are randomized but it can lead to a dilution of any observed treatment effects. 
Biomarker misclassification therefore represents a challenge within biomarker-
guided trials, and further sensitivity analyses may be needed to address its effect on 
the trial result. 
Another issue is that whilst it is relatively straightforward to look for the 
presence or absence of a particular mutation in a particular gene, it is much more 
difficult to be able to say with confidence that a gene is normal in order to be able to 
classify a patient. Therefore, the analytical validity of a biomarker in terms of 
sensitivity and specificity is a challenging but very important issue and 
understanding the accuracy of an assay is a necessary consideration. If a sample 
fails completely, it is easy to class it as failed; if there is a partial fail, this represents 
a difficult result to handle and in the case of partial failure it can be difficult to 
classify a patient based upon the result.  
Challenges can arise when a laboratory is required to change the staining 
machine and assay during the course of the trial. In this case it is likely that 
measurements taken prior to the change may need to be repeated using the newer 
technology or at a minimum calibration of the results investigated. Apart from the 
significant cost implications, it is also necessary to appropriately consider cases 
where the new result differs from the previous one. Conducting an analysis that is 
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stratified by the date the assay measurement changed may be an alternative way of 
handling these sorts of biomarker adaptations during the trial. 
Data sharing issues 
When a pharmaceutical company is involved in a trial, along with the clinical 
study report it may be expected that the trial data will be shared with the company 
at the end of the trial, within a data sharing framework, and this will be detailed in 
the contract. However, in early phase trials companies may want data to be shared 
in real time or at least at periodic intervals (e.g., to guide business decisions) during 
the trial. Current consensus suggests that this is not good practice for phase III 
trials. For single arm phase II trials which are more exploratory in nature opinions 
differ as to its merits, especially when treatments are being evaluated using a 
response endpoint. One argument against this type of data sharing during the trial 
is that historically, if you questioned why a phase II trial had failed, one reason was 
that the clinicians or chief investigators were too selective in picking their patients 
when they had a fixed threshold of responders to reach to call it a success (e.g., 
selecting patients more likely to respond creating a distorted cohort of patients in 
the latter part of the trial). Sharing data during the trial could result in such 
situations arising again.  
Further, whilst decisions in terms of the closure of strata are the responsibility 
of the trial oversight committees, pharmaceutical companies may wish to be 
involved in the decision making process. 
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Whilst data sharing requests from pharmaceutical companies are likely to be 
common in biomarker-guided trials, differing viewpoints in terms of how and 
when data should be shared can be particularly challenging for the trial 
management team. To ensure that good relations are maintained with all interested 
parties, it is recommended that a clear data sharing policy and common data 
standards are developed and agreed at the point of contract negotiation, prior to 
trial outset, with all aspects of decision-making explicitly stated as the remit of the 
independent trial oversight committee. 
Resources 
In terms of clinical trials unit (CTU) management ensuring the availability of 
appropriate resources is a challenge. Biomarker-guided trials require adequate 
funding for dedicated personnel. The complexity of the required IT support is 
frequently underestimated and essential for biomarker-guided trials. The 
complexity of the Case Report Forms (CRF) is a particular challenge, since the data 
required often varies between strata. Hence, there is a need for several different case 
report forms equivalent to having many separate trials but with the additional 
burden of needing a more sophisticated over-arching database structure. Protocol 
amendments lead to additional problems due to the fact that for just one 
amendment (e.g. an additional medical assessment), all CRFs require modification. 
The consequences of needing separate CRFs for different comparisons were 
observed in the FOCUS4 trial. The trial uses electronic data capture (eDC) where 
local site staff enter data directly into the database. When the trial was first set-up, it 
opened with only one molecular comparison and a single non-stratified 
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comparison. The aim was to have all cohorts eventually in one main database, 
however, this has proven difficult and it was decided to include future comparisons 
in separate databases, meaning that sites have to open a number of different 
databases to enter data for their FOCUS4 patients rather than just one. 
Furthermore, administrative support for tasks such as preparing site packs is 
often underestimated, and the need for collaboration between a clinical trials unit 
and biomarker labs adds further pressure onto resources. Challenges associated 
with such collaboration relate to laboratory agreements (e.g., impact on data 
sharing) and the processes for tracking, blinding and pseudo-anonymization of 
samples. In addition, specialist biomarker expertise is required, something which is 
not typically available within a trials unit.  
More complex work is also needed when adding new treatment groups to 
platform trials or making other adaptations to a trial. Several issues need to be 
considered at that time; in essence incorporating a new treatment group in a master 
protocol is equivalent to setting up a new trial, including protocol writing and case 
report forms development, database development, setting up of contracts, drugs 
supply etc. while recruitment, co-ordination and data collection for existing 
treatment groups continues. Further, whilst existing systems and processes may 
work with an initial small number of groups, they may not work as well with a 
much larger number of groups, and it is therefore difficult to predict level of 
resource upfront, leading to inefficiencies down the line.  
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POETIC faced several challenging issues, many of those relating to the need to 
extend the clinical trials culture across multidisciplinary teams involved at cancer 
diagnosis, and the integration of research protocols into busy clinics. For these 
reasons, a variety of pathways (different fresh tissue collection options) as well as 
different types of tissue (availability of biological and non-biological centres) were 
considered. 
To summarize, the resources required for efficient management of a 
biomarker-guided trial should not be under-estimated and clinical trial units in 
particular need to ensure that they are prepared in particular for the administrative 
burdens that come with such trials, and adequately cost them into any funding 
applications. 
Discussion 
At our workshop ‘Biomarker-guided trials: challenges in practice’ several practical 
challenges were considered:  
- Funding issues, including higher resources due to typical complexity of 
biomarker-guided trials, difficulties in making accurate cost predictions at the 
outset, confusion over who should meet biomarker testing costs and the need for 
sharing of knowledge and experience between researchers and funders’ regarding 
the implications of using such designs. 
- Ethical and regulatory issues, including uncertainty about whether amendments 
require new approvals, the need to maintain a collaborative relationship and 
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effective communication with HRA and regulators and issues relating to 
communications with patients. 
- Recruitment issues such as the difficulty in predicting an accurate recruitment 
rate, delays in setting up sites, and unknown patient dropout rates. 
- Issues arising in the tracking and monitoring of samples and laboratories when 
not all laboratory staff are GCP trained, the need for efficient sample processing and 
tracking, dealing with changing technologies, challenges of biomarker 
misclassification and the need to establish effective communication and 
collaboration between clinicians and laboratory staff to address current challenges. 
- Issues regarding data sharing agreements, particularly when working in 
collaboration with pharmaceutical companies. 
- Resourcing issues, including underestimation of the extent of IT and 
administrative support required, and of the complexity of databases and CRFs. 
Although many of the challenges discussed relate to the more complex biomarker-
guided trials such as umbrella trials, similar challenges can appear in biomarker-
guided clinical trials more generally. Likewise, we acknowledge that some of the 
challenges identified are equally relevant to more complex trials irrespective of 
whether they incorporate biomarkers or not (eg predicting the cost of 
adding/removing arms, approving amendments, CTU resource issues), whilst 
others are specific to biomarker-guided trials (eg predicting recruitment rates when 
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biomarker prevalence unknown, ethical issues from communicating results of 
biomarker tests, sample processing and laboratory challenges) .  
Despite the aforementioned challenges, the biomarker-guided trials discussed 
within this report represent successful research projects using novel designs, which 
will hopefully inform future practice. NLMT, for example, provides a great 
opportunity for widespread national collaboration with leaders from the lung 
cancer community within academia, the health service and the pharmaceutical 
industry, and direct collaboration with CRUK. It promises to make a real 
contribution to the knowledge on precision medicine by testing new drugs tailored 
to a specific biomarker-defined subgroup. 
Further, the FOCUS4 trial, uses an efficient Multi-Arm, Multi-Stage (MAMS) 
design which has proved to be particularly efficient in the mCRC disease setting 
where the progression-free survival (PFS) event rate is high and interim analyses 
are triggered quickly. Its other successes include having a strong collaborative trial 
management group with a very engaged overall Chief Investigator (CI), the use of 
different CIs for each comparison, early engagement with the Research Network, 
clear protocol structure and nomenclature as well as the single regulatory and ethics 
approvals.  
TOPARP demonstrated anti-tumour activity of olaparib in patients with 
advanced CRPC (Mateo J et al, N Engl J Med 373(18):1697-708) and was the first 
molecular treatment stratification in metastatic castrate resistant prostate cancer 
(mCRPC).  A successful collaboration between ICR, AstraZeneca and Cancer 
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Research UK (National Cancer Research Network Collaboration) led to the FDA 
granting olaparib breakthrough therapy designation based largely on the results of 
TOPARP-A. 
EU-PACT provides an example of an international, multi-site trial which, due 
to its pragmatic approach and adoption of the biomarker-strategy design allowed 
the improved treatment outcomes from using biomarker-guided approach to 
prescribing warfarin to be demonstrated. This has led to a subsequent matched-
cohort study which demonstrated the successful implementation of the biomarker-
guided approach into clinical practice(18), and a trial based on EU-PACT is 
currently being planned in Africa to test the clinical utility of a personalised 
approach to warfarin dosing in low-resource settings.  
To conclude, the examples of biomarker-guided trials considered here 
demonstrate the real benefits of adopting such designs, despite the teething 
problems resulting from using such novel methodologies. However, the significant 
investments required to successfully conduct such trials should not be 
underestimated, and it is imperative that the practical challenges they bring for 
clinicians, laboratories, regulators, academia, industry and patients as outlined 
above should be acknowledged and addressed at the outset. As the need for trials in 
stratified medicine increases however, it is anticipated that through experience 
stakeholders will become more familiar with the designs and the procedures 
involved in conducting and managing them will evolve and adapt accordingly. It is 
important therefore that the knowledge gained by those with experience of 
biomarker-guided trials is communicated to the wider research community such 
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that all stakeholders are educated about the complex issues that biomarker-guided 
clinical trials face and recommendations for how they may be overcome. 
Conflict of interest 
The authors do not have any competing interests to declare. 
Funding 
The workshop that led to this publication was funded by the MRC Network of 
Hubs for Trials Methodology: grant MR/L004933/1. 
Acknowledgements 
We wish to express our sincere appreciation to all the people who shared their 
expertise and experience with us during the preparation of this report. Our special 
thanks go to the people who participated in the workshop on “Practical challenges 
in the conduct of biomarker-guided clinical trials” and the MRC Hubs for Trials 
Methodology Research Network’s Stratified Medicine Working Group (SMWG). 
References 
1. Landeck L, Kneip C, Reischl J, Asadullah K. Biomarkers and personalized 
medicine: current status and further perspectives with special focus on 
dermatology. Exp Dermatol. 2016;25(5):333-9. 
2. Bailey AM, Mao Y, Zeng J, Holla V, Johnson A, Brusco L, et al. 
Implementation of biomarker-driven cancer therapy: existing tools and remaining 
gaps. Discov medicin. 2014;17(92):101-14. 
3. Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Biomarker-Guided 
Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. PLoS 
ONE. 2016;11(2):e0149803. 
32 
 
4. Antoniou M, Kolamunnage-Dona R, Jorgensen AL. Biomarker-Guided Non-
Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J Pers 
Med. 2017;7(1). 
5. Freidlin B, Korn EL. Biomarker-adaptive clinical trial designs. 
Pharmacogenomics. 2010;11(12):1679-82. 
6. Lin JA, He P. Reinventing clinical trials: a review of innovative biomarker 
trial designs in cancer therapies. Br Med Bull. 2015;114(1):17-27. 
7. Antoniou M, Jorgensen AL, Kolamunnage-Dona R. Fixed and Adaptive 
Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size. J 
Pers Med. 2017;7(4). 
8. Middleton G, Crack LR, Popat S, Swanton C, Hollingsworth SJ, Buller R, et 
al. The National Lung Matrix Trial: translating the biology of stratification in 
advanced non-small-cell lung cancer. Ann Oncol. 2015;26(12):2464-9. 
9. Phase II trial of olaparib in patients with advanced castriation resistant 
prostate cancer (TOPARP). [Available from: http://www.icr.ac.uk/our-research/our-
research-centres/clinical-trials-and-statistics-unit/clinical-trials/toparp. 
10. ATLANTIS: An adaptive multi-arm phase II trial of maintenance targeted 
therapy after chemotherapy in metastatic urothelial cancer. [Available from: 
http://www.crukctuglasgow.org/eng.php?pid=atlantis. 
11. PRIMUS 001  [Available from: 
http://www.crukctuglasgow.org/eng.php?pid=primus001. 
12. Trial of perioperative endocrine therapy - individualising care (POETIC). 
[Available from: https://www.icr.ac.uk/our-research/centres-and-
collaborations/centres-at-the-icr/clinical-trials-and-statistics-unit/clinical-
trials/poetic_trial. 
13. Robertson J, Dowsett M, Bliss J, Morden J, Wilcox M, Evans A, et al. Abstract 
GS1-03: Peri-operative aromatase inhibitor treatment in determining or predicting 
longterm outcome in early breast cancer – The POETIC* Trial (CRUK/07/015). 
Cancer Research. 2018;78(4 Supplement):GS1-03-GS1-. 
14. FOCUS4  [Available from: http://www.focus4trial.org/. 
15. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson 
T, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 
2013;369(24):2294-303. 
16. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG 
recommendations for reporting of incidental findings in clinical exome and genome 
sequencing. Genet Med. 2013;15(7):565-74. 
17. Roche MI, Berg JS. Incidental Findings with Genomic Testing: Implications 
for Genetic Counseling Practice. Curr Genet Med Rep. 2015;3(4):166-76. 
18. Jorgensen AL, Prince C, Fitzgerald G, Hanson A, Downing J, Reynolds J, et 
al. Implementation of genotype-guided dosing of warfarin with point-of-care 
genetic testing in three UK clinics: a matched cohort study. BMC Med. 2019;17(1):76. 
  
33 
 
Trial Disease Primary 
endpoint(s
) 
Number 
of arms 
Trial 
design 
Type of 
biomarker(s
) 
Role of 
biomarker(s) 
Responsibili
ty for overall 
management 
Primary 
funding 
source(s) 
Challenges 
NLMT Advanced non-
small cell lung 
cancer 
 
Best 
objective 
response; 
Durable 
clinical 
benefit; 
Progression-
free survival 
time 
 
8 Bayesian 
adaptive 
umbrella 
design 
Genetic 
markers 
To determine 
arm/treatment 
allocation 
Early Drug 
Development 
(EDD) Trial 
Management 
Team based 
within the 
Cancer 
Research UK 
Clinical 
Trials Unit 
(CRCTU), 
University of 
Birmingham 
Cancer 
Research 
UK 
Uncertainty 
regarding total 
costs of trial – 
resolved by 
submitting 
estimated 
future costs 
and CRUK 
providing 
agreement in 
principle; 
additional 
costs of 
biomarker 
analysis – 
resolved by 
funding 
molecular 
screening 
platform as 
separate 
entity; 
significant 
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dropout due to 
recruiting 
patients with 
advanced 
disease; CTU 
personnel 
required to 
interpret 
biomarker 
reports 
themselves to 
determine 
relevant 
treatment arm    
TOPARP Metastatic 
castration 
resistant 
prostate cancer 
Treatment 
response 
according 
to pre-
specified 
criteria 
 
TOPARP-
A: single 
arm 
TOPARP-
B:  
two-arm 
randomise
d  
 
TOPARP- A: 
Open-label, 
single arm, 
two part 
adaptive 
design 
phase II 
trial.  
TOPARP-B: 
Open-label, 
two-arm 
randomise
d, each arm 
with a 
Genetic 
markers 
TOPARP-A: 
Biomarker 
development - to 
identify 
predictive 
biomarkers of 
response to 
olaparib 
TOPARP B: 
Biomarker 
validation - 
biomarker 
guided patient 
Institute of 
Cancer 
Research, UK 
Trial run 
under the 
NCRN-AZ 
initiative 
(CRUK 
and AZ 
funded) 
Complex 
sampling 
collection and 
processing 
requirements 
outside 
standard 
pathway at 
sites.  QA 
sample 
failures at 
central labs 
which lead to 
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single stage 
phase II 
design.  
selection for 
eligibility to 
confirm sub-
group identified 
in A 
 
delays in 
biomarker 
results being 
available.  
Greater CTU 
and lab 
activity/resour
ce required to 
manage 
challenges and 
ensure 
collaborators’ 
expectations 
were met. 
ATLANTI
S 
Metastatic 
urothelial cancer 
Progressio
n-free 
survival 
3 Adaptive 
multi-arm 
design 
Homologous 
recombinatio
n deficiency 
and genetic 
markers 
To determine 
arm/randomisati
on treatment 
Clinical 
Trials Unit, 
University of 
Glasgow 
Cancer 
Research 
UK 
 
PRIMUS00
1 
Metastatic 
pancreatic 
cancer 
Progressio
n-free 
survival 
2 Adaptive 
design 
Genetic 
markers 
For subgroup 
analysis of 
primary 
outcome, and to 
determine 
eligibility for 
recruitment 
following interim 
Clinical 
Trials Unit, 
University of 
Glasgow 
Cancer 
Research 
UK 
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analyses 
SALONIC
A 
Ovarian cancer Progressio
n-free 
survival 
1 Sequence 
of single 
arm trials, 
but plans 
to 
progress 
to 
Bayesian 
adaptive 
randomise
d design 
Genetic 
markers 
Initially for 
subgroup 
analysis, and 
then to 
determine 
randomisation 
ratio 
Clinical 
Trials Unit, 
University of 
Glasgow 
N/A – 
planning 
stage 
 
TASTER Chronic 
Myeloid 
Leukaemia 
Progressio
n-free 
survival 
1 Series of 
single arm 
trials 
Biomarkers 
contributing 
to molecular 
signatures 
To determine 
eligibility for 
which single arm 
trial 
Clinical 
Trials Unit, 
University of 
Glasgow 
N/A – 
planning 
stage 
 
POETIC Breast cancer Relapse 
free 
survival 
2 Two-arm 
parallel 
randomise
d 
controlled 
trial 
Genetic 
marker and 
Gene 
expression 
profile 
To determine 
eligibility and for 
subgroup 
analyses 
Institute of 
Cancer 
Research, UK 
Cancer 
Research 
UK 
 
37 
 
FOCUS 4 Metastatic 
colorectal cancer 
Progressio
n-free 
survival 
I 3 
molecularl
y stratified 
trials and 
1 non-
stratified 
trial 
Multi-arm, 
multi-
stage 
umbrella 
design 
Genetic 
markers 
To determine 
arm/randomisati
on treatment 
MRC Clinical 
Trials Unit at 
UCL 
NIHR/MR
C EME 
Programm
e and 
Cancer 
Research 
UK 
Intensive CTU 
resource 
requirements 
for the multi-
tasking aspects 
of the adding 
and dropping 
arms design; 
High costs of 
running trial – 
resolved by 
securing joint 
funding 
between 
MRC/NIHR 
EME and 
Cancer 
Research UK 
and having 
trial conducted 
in a CTU with 
separate core 
funding;  
Delays in 
biomarker 
results 
turnaround 
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and failed 
samples; 
Pathology 
number 
discrepancies; 
Failure to send 
GCP 
compliant 
documents 
from 
pathology lab 
to CTU;  
Needing 
comparison-
specific CRFs 
therefore sites 
having to deal 
with several 
separate 
databases;  
EU-PACT Atrial 
fibrillation and 
venous 
thromboembolis
m 
Time in 
therapeutic 
INR range 
during first 
three 
months of 
treatment 
2 Two-arm 
parallel 
randomise
d 
controlled 
trial 
Genetic 
markers 
Predict 
therapeutic dose 
Wolfson 
Centre for 
Personalised 
Medicine, 
University of 
Liverpool 
European 
Commissio
n Seventh 
Framewor
k 
Programm
e  
Need for rapid 
turnaround of 
genotyping 
results to 
allow same-
day treatment 
initiation at 
39 
 
predicted dose 
– resolved by 
working with 
industrial 
collaborator to 
develop 
efficient point 
of care test  
 
